Arcutis Biotherapeutics has appointed Chris Peetz to its Board of Directors as of July 15, 2026. Peetz brings extensive experience leading biopharmaceutical companies through growth phases, product development, and strategic acquisitions. His addition is expected to support Arcutis' strategy to grow its ZORYVE franchise and expand its pipeline in immuno-dermatology. Peetz currently leads Mirum Pharmaceuticals and has a strong background in finance and corporate development within the biotech sector.
Anteris Technologies announced favorable 30-day clinical outcomes for its Medium-size DurAVR Transcatheter Heart Valve (THV) in 22 patients with severe aortic stenosis. The valve showed excellent hemodynamics with low pressure gradients, large effect...
A landmark P4 randomized trial showed that CT-guided percutaneous coronary intervention (PCI) delivers clinical outcomes comparable to the gold-standard intravascular ultrasound (IVUS) at one year, while reducing procedure time by 27% and contrast us...
Canary Capital CEO Steve McClurg predicts that institutional buying via ETFs and digital asset treasury companies will lead the next crypto market phase, potentially pushing large-cap altcoins ahead of Bitcoin. He highlights that assets with real tra...
Binance transferred 21,750 Bitcoin, worth about $1.69 billion, between its cold and hot wallets. This transfer does not indicate customer withdrawals but is part of internal wallet management. On November 1, the first day Binance resumed withdrawals,...
Circle has released technical guidance for using its Cross-Chain Transfer Protocol (CCTP) to enable issuer-controlled transfers of ERC-20 tokens beyond just USDC. This update allows more tokens to move seamlessly across supported blockchain networks,...
